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types. We describe here a protocol for rapid isolation of myeloid cells from tumor-harboring
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SUMMARY
Current single-cell RNA sequencing (scRNA-seq) protocols are limited by the
number of cells that can be simultaneously sequenced, restricting the ability to
resolve heterogeneity of rare cell types. We describe here a protocol for rapid
isolation of myeloid cells from tumor-harboring mouse cerebellum without cell
sorting to minimize cell damage for scRNA-seq. This protocol includes the pro-
cedures for further enrichment of myeloid cells using CD11b+ magnetic beads,
followed by the generation of scRNA library and sequencing analysis.
For complete details on the use and execution of this protocol, please refer to
Dang et al. (2021).
BEFORE YOU BEGIN
Mouse models to study brain tumor immune microenvironment include genetically engineered
autochthonous models, orthotopic injection of syngeneic cell lines, and injection of viral constructs
expressing oncogenes. Please refer to the following publications for a detailed discussion of various
mouse models for brain tumors such as medulloblastoma and high-grade gliomas: Simeonova and
Huillard (2014), Hetze et al. (2021), and Li and Langhans (2021). The time required to generate tu-
mors will depend on the specific model. The protocol described here uses the sonic hedgehog sub-
group of medulloblastoma (SHH-MB) that spontaneously develops in Ptch1+/ p53/ mice. These
mice develop tumor with complete penetrance by 8-weeks of age (Wetmore et al., 2001).
The desired number of myeloid cells to sequence will depend on many factors including the density
and complexity of myeloid cells in the tumor as well as the desired sequencing depth per cell. There-
fore, it is important to perform flow cytometry or other orthogonal analyses to estimate density and
complexity of tumor-associated myeloid cells prior to planning scRNA-Seq. In general, we aim to
have 50 to 100 cells of each predicted subset of interest. For more thorough discussions, including
a rationale for this quantity, please refer to following publications: Shapiro et al. (2013), Nguyen et al.
(2018), and Zhang et al. (2020).
To enrich samples for tumor-infiltrating myeloid cells, it is ideal to start with tumor tissue with min-
imal surrounding normal brain tissue. This is relatively easy for tumors that have features discernible
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under a dissection microscope or if tumor cells express unique surface markers or reporter genes
(e.g., fluorescent proteins). Tumor cells in Ptch1+/ p53/ mice described here do not express
such unique markers or reporter, which is also true for most murine models and human tumors.
Hence, the protocol below describes isolation of myeloid cells from brain tissue containing tumor
cells, which is applicable to a wide variety of brain tumors.
Note: Institutional permission should be obtained for the animal studies. Animal work pre-
sented here was conducted according to the National Institutes of Health guidelines and
approved by the Institutional Animal Care and Use Committee at the University of
Pennsylvania.
Note: We used Ptch1+/ p53/ mice at 8 weeks of age male mice before they developed
symptoms of SHH-MB. All Ptch1+/ p53/ mice are predicted to have tumors at this age,
nevertheless we MR imaged mice at 8 weeks of age to confirm the presence of tumor and iso-
lated cells from tumor-harboring cerebellum. We recommend using brain tissue that contains
the largest proportion of tumor volume possible before animals reach predetermined symp-
tomatic endpoints. This will allow for the least amount of homeostatic microglia from brain tis-
sue surrounding the tumor to be present in the sample. We provide recommendations on how
to identify this population in the final scRNA-Seq data analysis section.
Note: We ascertained that the SHH-MB model contains significant myeloid infiltrates by flow
cytometry and immunohistochemistry prior to scRNA-Seq (see Figures 2B, 5A, and S5E in
Dang et al., 2021).
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Chemicals, peptides, and recombinant proteins
Percoll Sigma-Aldrich 17-0891-02
Dulbecco’s 13PBS MilliporeSigma D8537
Dulbecco’s 103PBS MilliporeSigma 59331C
RPMI1640 Medium Fisher Scientific MT10-040-CM
Trypan Blue Solution, 0.4% Thermo Fisher Scientific 15250061
Bovine serum albumin Millipore Sigma A9647
EDTA Thermo Fisher Scientific AMB9261
Antibodies
BV510 Cd45 anti-mouse antibody (1:200) BioLegend 103138;
RRID:AB_2563061
PE-Cy7 Cd11b anti-mouse antibody (1:200) Fisher Scientific 25-0112-82;
RRID:AB_469588
PerCp/Cy5.5 Ly6G anti-mouse antibody (1:200) BioLegend 127615;
RRID:AB_1877272
Critical commercial assays
CD11b+ magnetic MicroBeads Miltenyi Biotec Inc 130-092-636
CD45+ magnetic MicroBeads Miltenyi Biotec Inc 130-052-301
LS columns Miltenyi Biotec Inc 130-042-401
Chromium Next GEM Single Cell 3ʹ Kit v3.1 10x Genomics PN-1000268
Chromium Next GEM Chip G Single Cell Kit 10x Genomics PN-1000120
Dual Index Kit TT Set A, 96 rxns 10x Genomics PN-1000215
Chromium i7 Sample Index Kit 10x Genomics PN-120262
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Deposited data
scRNA-seq of Cd11b+ myeloid cells from Ptch1+/-p53/ mice Dang et al. (2021) GEO: GSE166691
Experimental models: Organisms/strains
Mouse: Ptch+/- The Jackson Laboratory 030494
Mouse: Tp53/ The Jackson Laboratory 002101
Software and algorithms
Seurat package (v.3.0) Satija et al. (2015) https://satijalab.org/seurat/
SingleR Aran et al. (2019) https://bioconductor.org/
packages/release/bioc/
html/SingleR.html
R R Core Team http://www.R-project.org
Other
Spinal needle 20G 6’’ Medline BD405211
70uM cell strainer CELLTREAT 229483
Cole-Parmer homogenizer 10 mL Cole-Parmer UX-44468-03
5 mL syringe Fisher Scientific 309646
MidiMACS separator Miltenyi Biotec Inc 130-042-302
MACS Multistand Miltenyi Biotec Inc 130-042-303
Chromium Single Cell Controller 10x Genomics CG00050
C1000 Touch thermal cycler Bio-Rad Laboratories 1851197
Tape Station High Sensitivity D5000 Reagents (used for cDNA QC) Agilent Technologies 5067-5593
Tape Station High Sensitivity D5000 ScreenTape (used for cDNA QC) Agilent Technologies 5067-5592
Tape Station High Sensitivity D1000 Reagents (used for Library QC) Agilent Technologies 5067-5585
Tape Station High Sensitivity D1000 ScreenTape (used for Library QC) Agilent Technologies 5067-5584
KAPA Library Quantification Kit for Illumina Platforms Roche Holding AG 07960336001 - KK4873
NovaSeq 6000 sequencer Illumina 20012850
NovaSeq 6000 SP Reagent Kit v1.5 (100 cycles) flow cell Illumina 20028401
PhiX Control v3 Illumina FC-110-3001
SPRI Select 60 mL Beckman Coulter B23318
Stock Isotonic Percoll (SIP100), volume per sample (7.5 mL/sample [6.85 mL + 10%])
Reagent Final concentration Amount
Percoll – 6.75 mL
Dulbecco’s 103 PBS 13 0.75 mL
[Prepare day of experiment and keep at room temperature (20C–24C) ]
70% Percoll 70% (SIP70), volume per sample (5.5 mL/sample [5 mL + 10% extra)
Reagent Final concentration Amount
SIP100 70% 3.85 mL
Dulbecco’s 13PBS - 1.65 mL
[Prepare day of experiment and keep at room temperature]
MACS buffer (500 mL total)
Reagent Final concentration Amount
103 Dulbecco’s Phosphate-Buffered Saline (sterile PBS) 13 50 mL
Bovine Serum Albumin (BSA) 0.5% 2.5 g
0.5 M EDTA (pH 8.0) 2 mM 2 mL
Distilled water (dH2O) - Fill to 500 mL
[Filter through a polystyrene membrane under sterile conditions; store at 4C for up to 2 weeks.]
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CRITICAL: Keep MACS buffer on ice and use it cold during experiment.
STEP-BY-STEP METHOD DETAILS
This protocol has five main sections (see below). Sections 1 and 2 are specific to this protocol while
sections 3–5 are generic and depend on user preferences.
Section 1: Isolation of myeloid cells from tumor-bearing brain tissue with Percoll.
Section 2: Further enrichment of myeloid cells using CD11b+ magnetic beads.
Section 3: Generation of Single Cell RNA library using the 103 chromium platform.
Section 4: Sequencing.
Section 5: Analyses of sequencing data.
Section 1: Isolation of myeloid cells from tumor-bearing brain tissue with Percoll
Timing: 4 h
Myeloid cells are isolated from brain tumors using a fixed gradient Percoll separation.
Homogenize brain tumor
(Perform at room temperature)
1. Resect brain tumor (Figure 1).
a. After euthanizing the mouse, remove the head of the mouse using a pair of scissors.
b. Cut away the skin (Figure 1A) and excess neck muscle until the brain stem can be seen (Fig-
ure 1B).
c. Starting from the brain stem, cut upward along the sagittal suture applying as little pressure as
possible to the brain itself (Figure 1C).
d. Peel each hemisphere of the skull away from the brain to the side (Figure 1D).
e. With a spatula or foreceps, remove the brain from the base of the skull and cut long nerve fi-
bers to detach the brain (Figures 1E and 1F).
f. For removal of the cerebellum, gently push the cerebellum with tumor away from the brain-
stem and detach the nerve fibers (Figures 1H and 1I). We used the entire cerebellum contain-
ing bilateral medulloblastomas.
Note: For tumors that are highly vascularized and intravascular immune cells are predicted to
be high, perfuse mouse with 10 mL ice-cold PBS through the left ventricle prior to resection.
For a detailed protocol on perfusing rodent, refer to Gage et al. (2012). Alternatively, immune
cells from peripheral blood can be identified during the analysis of the single-cell data using
published data sets obtained from cells of peripheral blood (Dang et al., 2021).
2. Add 5 mL RPMI solution and tumor into a 10 mL glass homogenizer and homogenize tissue.
3. Place a 70 mm cell filter on a 50 mL conical tube and pipet onto it the homogenate to filter out cell
clumps. Transfer the flow through into a 15 mL conical tube.
Percoll gradient-based isolation of myeloid cells
(Perform at room temperature at the bench. Sterile conditions are not needed.)
4. To cell suspension, add RPMI solution to make a total of 7 mL. Then add 3 mL SIP to cell suspen-
sion and mix by pipetting to create 10 mL cell suspension in 30% Percoll.
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5. Take up 5 mL of 70% Percoll solution in a 5 mL syringe attached to a spinal needle. Insert the nee-
dle into the cell suspension until the bevel reaches the bottom of the conical tube. Gently and
slowly, eject 70% Percoll layer below the 30% Percoll cell suspension layer.
CRITICAL: To minimize turbulence to make a sharp, demarcating line between the two
layers, make sure that no air bubbles are in the needle or syringe. Withdraw the needle
with a slow, smooth motion while keeping the needle parallel to the side of the tube.
Note: If spinal needles are not available, perform the layering in the reverse order. First,
pipette 5 mL of 70% Percoll solution into a 15 mL tube and slowly pipette onto it the 10 mL
of cell suspension in 30% Percoll with a P1000 pipet. This should be performed gently to
ensure a sharp, demarcating line between the two layers.
Note: If two layers are not clearly seen, recheck original concentration of 30% Percoll cell sus-
pension and 70% Percoll to make sure the correct percentage of Percoll was made for each.
6. Carefully and gently, carry the tubes to a centrifuge set at room temperature. Set the centrifuge
acceleration to maximal speed and deceleration to 0 to eliminate turbulence which causes un-
wanted mixing of the two layers disrupting the gradient. Spin the gradient mixture at 500 3 g
for 30 min. This spin will take 35–40 min because of the slow deceleration.
Figure 1. Resection of the mouse brain cerebellum with tumor
(A) Peeling the skin away from the skull.
(B) One arm of the scissors is inserted into the foramen magna where the brainstem runs through.
(C) Cutting skull along the sagittal suture.
(D) Removal of skull.
(E) Removal of the brain starting at the frontal lobe.
(F) Disconnecting nerve fibers from the brainstem.
(G) On the left is a normal brain. On the right is a brain with tumor. This mouse was symptomatic and had hydrocephalus resulting in a larger brain
volume above the tentorium as well. Folia of the cerebellum are no longer discernible.
(H) Removal of the cerebellum away from the brainstem (white).
(I) Disconnecting the nerve fibers from the brainstem to the cerebellum.
(J) Cerebellum with tumor is fully removed.
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Note: Percoll separation is optimized when the solution is at room temperature and the spin-
ning is done in a centrifuge set at room temperature.
CRITICAL: Set the centrifuge acceleration to maximal speed and deceleration to 0 to elim-
inate turbulence during deceleration which can cause unwanted mixing of the two layers.
Optional: If you wish to isolate a broader collection of immune cells including lymphocytes,
use a 40/80 Percoll gradient, a spin speed of 325 3 g for 30 minutes, and CD45 microbeads
in section 2. Use the following steps.
a. Prepare the following stock solution:
i. Stock Isotonic Percoll SIP 100% (SIP100), volume per sample (9.3/sample [8.4 mL+ 10%
extra])
ii. 80% Percoll, volume per sample (5.5 mL/sample [5 mL+10% extra])
b. Homogenize tissue as described above. Bring cell suspension volume up to 6mL and add 4mL
of SIP to make 10 mL of 40% Percoll cell suspension. Layer 80% Percoll beneath the 40% Per-
coll layer using method described above. Spin at 325 3 g for 30 min.
7. Gently remove the tube from the centrifuge. A white, thin layer of myelin will be seen at the top
of the tube. Additionally, a cloudy interface layer of several millimeters thick containing myeloid
cells will be seen at the interface between the two Percoll layers.
8. Aspirate and discard the top white layer that contains myelin fragments.
9. Using a spinal needle attached to a 5 mL syringe, insert the needle into the gradient until the tip
hits the interface layer and gently aspirate into the syringe the interface layer (2–3 mL depend-
ing on the number of cells that determines the thickness of the layer) and gently transfer to a
fresh 15 mL conical tube.
10. To wash cells and remove Percoll, add ice-cold 12 mL MACS buffer. Mix with gentle pipetting.
Reset centrifuge deceleration back to maximum and temperature to 4C. Spin cell suspension
300 3 g for 7 min.
11. Discard supernatant and resuspend cell pellet in 1 mL of coldMACs buffer and transfer to 1.5 mL
microcentrifuge tube.
12. Spin at 300 3 g speed for 1 min.
13. Discard supernatant and resuspend cell pellet in 90 mL of MACs buffer (per 107 total cells).
Note: The number of cells in this sample is dependent on the density of myeloid cells in
tumor and size of tissue that was homogenized. Quantification can be performed with a
cell counter or hemocytometer. Flow cytometry with common myeloid markers can be
performed to confirm the quality of myeloid enrichment. Percoll purified cells in mouse
medulloblastoma that occupy the majority of the cerebellum is generally less than 107
in quantity.
Reagent Final concentration Amount
Percoll - 8.37 mL
103 PBS 13 0.93 mL
Reagent Final concentration Amount
SIP 80% 4.4 mL
13 PBS - 1.1 mL
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Section 2: Further enrichment of myeloid cells using CD11b+ magnetic beads
Timing: 2 h
Note: The detailed protocol is described in the manufacturer’s protocol (https://www.
miltenyibiotec.com/US-en/products/cd11b-microbeads-human-and-mouse.html#gref; click
‘‘Data sheet’’). Below are the major steps and conditions used in Dang et al. (2021).
14. Incubate cell suspension with CD11b MicroBeadsTM by adding 10 mL of microbeads to every
90 mL of cell suspension and incubate for 15 min on ice.
Optional: CD45 MicroBeadsTM can be used with cells collected from a 40/80 Percoll gradient
to capture lymphocytes and myeloid cells.
15. To wash cells, resuspend in 1 mL of MACs buffer and spin at 300 3 g for 10 min.
16. Discard supernatant and resuspend in 500 mL of coldMACs buffer andmix with gentle pipetting.
17. While cells are being prepared in step 14, set up an LS column in the MidiMACS separator
mounted to a MACS Multistand (following manufacturer’s recommendation in protocol listed
above) over a 15 mL conical tube to collect flow through and wash with 3 mL of cold MACS
buffer.
18. Apply the cell suspension onto the column and wait for the solution to run through the column.
19. Then wash the column 33 with 3 mL cold MACS buffer.
20. Remove the column from the separator and place it on a new 15 mL conical tube.
21. Pipette 5 mL of cold MACS buffer onto the column and immediately flush out magnetically
labeled cells by applying and pushing the plunger supplied with the column.
22. Spin at 300 3 g for 5 min.
23. Discard supernatant. Since it can be difficult to remove all supernatant from a 15mL conical tube
without disrupting a small cell pellet, remove as much supernatant as possible. Then add 1 mL
cold MACS buffer. Mix with gentle pipetting and transfer cell suspension to a 1.5 mL microcen-
trifuge tube. Spin at 500 3 g for 1 min to pellet the cell. Remove as much supernatant as
possible. Save the supernatant in case not all cells are pelleted.
24. Resuspend cells in desired volume and buffer appropriate for the scRNA-sequencing platform.
For 103 Genomics, we recommend using 13PBS (calcium and magnesium free) containing
0.04% weight/volume BSA (400 mg/mL). BSA is added to minimize cell losses and aggregation.
Note: If the desired volume is uncertain, we recommend resuspending cells in about 50–
100 mL of buffer, which will allow for enough volume for cell counting and a cell concentration
that may be approximately appropriate for loading for cDNA preparation. Adjustment to vol-
ume (either more concentrated or dilute) can be made after the cell count.
CRITICAL: Buffer should not contain excessive amounts of EDTA (>0.1 mM) or magnesium
(>3 mM) because those components will inhibit the reverse transcription reaction.
CRITICAL: Tominimize physical damage to cells it is important to pipette gently and slowly
during cell resuspension steps. Use wide-bore pipette tips to minimize cell damage.
25. Using trypan blue and a hemocytometer, count the number of viable cells to determine quantity
of sample to be used for library preparation. For detailed instructions on counting cells, refer to
the following online protocol by Moore (2012) (https://www.protocols.io/view/
counting-cells-with-hemocytometer-nxsdfne).
Note: Cell suspensions should also be checked visually for debris or cell aggregates because
these can clog microfluidic channels. If observed, additional pipetting or filtering may be
ll
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required to obtain optimal performance. Pipetting should be done gently and carefully to
avoid lysing or damaging cells. Alternatively, filter cell suspension with one of the following
cell strainers: Flowmi Cell Strainer (40 micron, Fisher Scientific 14-100-150) or MACS Smart-
Strainer (30 micron, Miltenyi 130-098-458)
Note: If cell concentration is much lower than expected, check the concentration of saved su-
pernatants and re-pellet the supernatant at a higher centrifugation speed. Cells may not have
been efficiently pelleted at the initial speed or were lost in the cell strainer.
26. Dilute or concentrate the solution to obtain cell suspension concentration between 700 and
1200 cells/mL for optimal chip loading.
Note: To the determine the optimal suspension volume to achieve target cell recovery, refer
to the Cell Suspension Volume Calculator Table on page 30 of the ChromiumNext GEMAuto-
mated Single Cell 30 Reagent Kits v3.1 User Guide (CG000286) (https://assets.ctfassets.net/
an68im79xiti/5qIua7LwDKxoNEvHJnYqcB/c778731aa23ca5e51e1aa5d1c8941828/
CG000286_ChromiumSingleCell3-_v3.1_Automation_UG_RevB.pdf).
CRITICAL: Once the target cell concentration is obtained, place the cells on ice immedi-
ately. Cell suspension should be loaded onto the chip for library preparation as soon as
possible, ideally within 30 min.
Section 3: Generation of Single Cell RNA library using the 103 chromium platform
Timing: 20 h
Note: The experiments in Dang et al. used Chromium Single Cell 30 v2 Chemistry, and libraries
sequenced on the Illumina HiSeq 2500. The v2 chemistry kits are no longer commercially avail-
able from the manufacturer. Therefore, the methodology described below is for the 30 kit.
More detailed instructions are provided on the manufacturer’s website (https://support.
10xgenomics.com/single-cell-gene-expression/library-prep/doc/
user-guide-chromium-single-cell-3-reagent-kits-user-guide-v31-chemistry-dual-index). Here
we describe the major steps.
Note: Next GEM (Gel Bead-In EMulsions) is a technology that is built on a new chip architec-
ture, the Next GEM Single Cell 30 Reagent Kits v3.1 and Next GEM Chip G Single Cell Kits
allow for a high number of detected genes, minimizes the number of barcodes that can be in-
terpreted to come from more than one cell, 65% capture rate, and is compatible with both
whole cells and nuclei. The kit contains Poly(dT) primer that enables the production of bar-
coded, full-length cDNA from poly-adenylated mDNA. This kit also allows add-on features
such as cell surface protein, CRISPR screening, and cell multiplexing.
27. Prepare a Chromium Next GEM Chip G in a Chromium Next GEM Secondary Holder and
dispense 50% glycerol into all unused wells.
28. Prepare the barcodemaster mix using RT Reagent B, Template SwitchOligo, Reducing Agent B,
and RT Enzyme C. Add the cell suspension to the master mix (with/without water depending on
the stock concentration) and mix by pipetting.
CRITICAL: Do not add nuclease-free water directly to single-cell suspension. Add
nuclease-free water to the Master Mix if needed.
29. Load the 70 mL final mixture into row 1 of the chip. Load 50 mL of vortexed gel beads into row 2
and 45 mL of partitioning oil in row 3.
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CRITICAL: Wait 30 s after adding the gel beads into the chip.
30. Place a gasket over the chip and attach it to the Secondary Holder. Load the chip into a Chro-
mium Single Cell Controller instrument for GEM (Gel Bead-In EMulsions) generation. This pro-
cess takes about 18 min.
31. Perform GEM-RT step in a thermal cycler. We used a C1000 Touch thermal cycler (BIO-RAD).
The thermal cycler protocol is the following: 45 min at 53C, 5 min at 85C, and hold at 4C.
Note: cDNA generated at this stage can be stored at 20C for up to a week.
32. Perform post-GEM clean up
a. Add Recovery Agent and invert to mix. Biphasic mixture will separate with the partitioning oil
in pink on the bottle.
Note: GEM generation occurs in narrow microfluidic channels so occasionally a clog may
occur. Clogs can be noticed when less than 100 mL of gel emulsion with beads is recovered
from the well and presence of heterogenous GEM emulsion (Figure 2). Clogs are generally
caused by a few reasons: (1) contamination of sample with debris and presence of cell clumps
which should be removed with strainers/filters before loading; (2) overloading the chip with
excess cells; (3) improper handling of gel beads which form the clog; to minimize the risk of
gel bead clogging, completely thaw and vortex the gel beads before processing, handle the
beads in a sterile environment, and store the chips in a clean area free of dust. If a clog occurs,
ideally the experiment should be repeated, but if the starting material is no longer available,
it is possible to proceed with the protocol and generate cDNA, but the number of recovered
cells will be lower.
b. Collect the clear aqueous phase on top
c. Add a master mix containing Dynabead MyOne SILANE beads, Reducing Agent B, Cleanup
Buffer and water.
d. Incubate for 10 min with pipet mixing at 5 min.
e. Place tubes on 103Magnetic Separator (High position) until the solution clears.
f. Remove the supernatant and wash the beads with ethanol.
g. Elute with elution buffer off magnet
h. Put back on the magnet to pull down beads.
i. Transfer 35 mL of the sample to a new tube.
33. To amplify cDNA add AmpMix and cDNA Primers to the sample and place in the thermal cycler
using the following protocol.
Note: The number of cycles depends on the desired targeted cell recovery. The goal is to
generate sufficient mass for library construction.
PCR cycling conditions
Steps Temperature Time Cycles
Initial Denaturation 98C 3 min 1
Denaturation 98C 1 min 25–35 cycles
Annealing 63C 20 s
Extension 72C 1 min
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34. Clean the cDNA
a. Add SPRIselect Reagent containing magnet beads to make a final 0.63 solution of the re-
agent.
b. Incubate for 5 min and place on the magnet until the solution clears.
c. Remove the supernatant.
d. Wash beads with ethanol x2.
e. Place on the magnet and remove residual ethanol.
f. Elute cDNA with elution buffer.
35. Perform quality control with a 1:10 diluted sample on the D1000 High Sensitivity kit, an auto-
mated electrophoresis platform. After cDNA amplification and SPRI cleanup, the size of the
cDNA fragments should be between 400 to 9000 bases. A high quality library preparation
should yield an abundance of cDNA within that size range (Figure 3).
Note: Agilent Bioanalyzer, Agilent TapeStation, and LabChip are the recommended methods
for accurate quantification. The total yield will vary depending on the number of PCR cycles
used during cDNA amplification, the number of cells targeted, and the RNA content per
cell. It is also possible to use Qubit Fluorometer and Qubit dsDNA HS Assay Kit as an alterna-
tive QC method; in this case, it is necessary to multiply the cDNA concentration reported via
the Qubit Fluorometer by the elution volume (40 mL) to obtain the total cDNA yield in
nanograms.
Figure 2. Tips 3 and 8 are not homogeneous and have an excess of partitioning oil, indicating a clog
The other tips are successfully generated GEM emulsions.
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Note: Total cDNA yield is highly dependent on the cell type, cell preparation, and the number
of cells loaded onto the chip. Low cDNA recovery may be result of low cell viability, RT inhib-
itory contaminants, sample clog, loss of cDNA during clean-up steps, or low total mRNA con-
tent per cell. If yield is low, add an extra 1–2 PCR cycles in the cDNA amplification step.
36. Proceed to construction of dual index library by starting with 10 mL of cDNA sample and per-
forming fragmentation, end-repair, and A-tailing in a joint reaction.
37. Purify sample using a dual-sided 0.63/0.83 bead:sample ratio with SPRIselect Reagent.
38. Perform adapter ligation by mixing each sample with a master mix consisting of ligation buffer,
DNA ligase, and Adapter Oligo.
39. Perform post-ligation cleanup with 0.83 SPRIselect Reagent purification.
40. Perform sample indexing PCR using Amp Mix and Dual Index TT Set A followed by a final size-
selection consisted of a dual-sided 0.63/0.83 bead:sample ratio.
41. After library construction, run the final library either on a Bioanalyzer or TapeStation High Sensi-
tivity kits at 1:10 dilution. The typical size distribution for final libraries is between 300 and
1000 bp. The trace should be similar to the high-grade sample in Figure 4 below.
42. Determine the average fragment size from the trace, this will be used as the insert size for library
quantification.
CRITICAL: Additional peaks may be present on the electropherogram trace. If there are
peaks around 200 bp, this may indicate carryover adaptor/primer dimers in the final library
and may affect sequencing results. If this occurs, perform an additional 1.03 SPRIselect
cleanup prior to sequencing to remove adaptor dimers. Perform this step only if the total
library yield is sufficient because an extra clean up may lose approximately 40% of the li-
brary material. If the total library yield is insufficient, we recommend performing a new li-
brary preparation from left-over amplified cDNA.
43. To determine the library concentration, perform qPCR using KAPA Library Quantification Kit for
Illumina Platforms by following the manufacturer’s recommendations (https://www.n-genetics.
com/products/1104/1024/17225.pdf) for qPCR-based quantification. Determine the concen-
tration based on insert size derived from the Bioanalyzer/TapeStation trace in the previous step.
44. Dilute the libraries to 1.75 nM and pool in equal proportions.
Section 4: Sequencing
Note: Sequencing time depends on the flow cell type. The time below is based on the SP 100
cycles V1.5 flow cell on the NovaSeq 6000 Illumina sequencer. This flow cell can generate
about 650–800 million reads and can fit up to four 30GEX libraries for a targeted capture
quantity of 10,000 per sample.
Figure 3. Examples of high and poor quality control traces of cDNA (D1000 High Sensitivity kit, TapeStationTM, Agilent)
The bad quality sample yielded significantly less cDNA.
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Timing:  24 h
45. Sequence the library. We performed sequencing on the NovaSeq 6000 with the run parameters
recommended by the 103 user guide: Read 1–28 cycles, i7 index – 10 cycles, i5 index – 10 cy-
cles, Read 2–90 cycles.
Note: By default, 1% of PhiX was added to the sequencing run for quality control monitoring.
103 Genomics recommends sequencing a minimum of 20,000 reads/cell.
Section 5: Analysis of sequencing data
46. Using a 103 Chromium Cell Ranger with instructions from the tutorial available online (https://
support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/using/
tutorials), generate three files: barcodes.tsv, genes.tsv, and matrix.mtx.
47. Use Seurat (Satija et al., 2015) (that runs in R or R Studio) or equivalent tool to analyze the data.
Tutorials are available for Seurat at https://satijalab.org/seurat/articles/get_started.html. Data
integration to eliminate batch effect should be considered, especially when combining samples
ran at different times.
48. Annotate immune cells using key markers for specific cell types or use SingleR (Aran et al., 2019)
algorithm that will allow you to import data from the Immgen database as a library reference.
49. To identify homeostatic microglia that are present in normal brain tissue, import published data
(Li et al., 2019; Dang et al., 2021) as a library reference. Alternatively, samples of homeostatic
microglia (from a normal brain) and peripheral blood (from mouse without tumor) can be
sequenced and batched together with tumor-associated macrophages. Please see Dang
et al. (2021) for detailed methods on identification of tumor infiltrating monocytes and homeo-
static microglia during analysis.
EXPECTED OUTCOMES
The application of this protocol significantly enriched myeloid cells from tumor-bearing cerebellum,
which was dominated by microglia, macrophages and monocytes (Figure 5). The minimal use of sur-
face markers (CD11b only) and the avoidance of enzymatic tissue digestion step in this protocol
Figure 4. Examples of high and poor quality control traces of library sample obtained from D1000 High Sensitivity
kit (TapeStationTM, Agilent)
In the low grade sample there is an extra 252 bp peak from contaminated cDNA. One additional SPRI cleaning cycle
using a 13 ratio removed the contaminant.
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minimizes the potential variations in the enriched cell population between samples or experiments
due to differences in cell-surface epitope density. We also corroborated our findings from scRNA-
seq with flow cytometry to rule out potential selection bias in our protocol (Figure 6).
LIMITATIONS
A limitation of this protocol is that the myeloid cells isolated are not strictly from the tumor micro-
environment. We have tried to ensure tumor-association of these cells in our model system by (1)
confirming the presence of tumor by MRI prior to euthanizing the mice and (2) identifying the tumor
by gross morphology and dissecting out the tumor. Nonetheless, the findings from scRNA-seq of
cells isolated in this manner can be validated within the tumor microenvironment by subsequent his-
tology as we showed in Dang et al. (2021). Emerging technologies in spatial genomics may eventu-
ally allow us to circumvent these generic issues of sequencing cells in suspension.
The limitations associated with the 103 chromium platform and library chemistry as well as Illumina
sequencing have been extensively covered in the literature. However, the first two sections of this
protocol are independent and can be applied to other single cell and/or sequencing platforms.
The computational analyses of the scRNA-seq data described here and in Dang et al. has its limita-
tions and were selected based on the goals of the study. Nonetheless, there are wide varieties of
analytical methods available depending on the objectives and expertise of the user.
TROUBLESHOOTING
Problem 1
After homogenizing brain tumor tissue, cell clumps are visible (step 1).
Potential solution
Add DNAse to HBSS buffer before homogenizing.
Problem 2
No Percoll gradient after centrifugation (step 7).
Potential solution
Check to make sure deceleration was set to 0.
Problem 3
Significantly lower myeloid cell staining on flow cytometry after Percoll gradient purification (step
13).
Figure 5. Comparison of scRNA-seq of myeloid cells isolated by the protocol described above (with 30/70 Percoll
separation) with scRNA-seq of all brain leukocytes isolated using CD45 beads (with 40/80 Percoll separation)
The UMAP projection validates myeloid enrichment (left) with our method. Data analysis was performed with data
integration and annotation using SingleR with Immgen database as the reference library.
ll
OPEN ACCESS
STAR Protocols 2, 100957, December 17, 2021 13
Protocol
Potential solution
Make sure all myelin has been removed as it can interfere with antibody binding.
Problem 4
The flow of cell suspension through LS column is too slow or stops entirely (step 18).
Potential solution
The column is likely clogged which can be due to excessive cells or clumping of cells in the sample.
Retrieve sample that has not entered the column, dilute it with more MACs buffer, and pipet gently
to separate cells. Apply sample to a newly prepped column.
Problem 5
Cell viability is much lower than expected after isolation and only debris is seen (step 25).
Potential solution
Use alternate buffer listed below with up to 10% FBS or up to 2% BSA to maintain cell health with
little to no adverse downstream effects:
Dulbecco’s Phosphate-Buffered Saline (DPBS)
Hank’s Balanced Salt Solution (HBSS)
If cell viability cannot be maintained in one of these buffers, it is also possible to wash and resuspend
(steps 23 and 24) in medias listed below:
Eagle’s Minimum Essential Medium (EMEM) + 10% FBS
Dulbecco’s Modified Eagle Medium (DMEM) + 10% FBS
Iscove’s Modified Eagle Medium (IMEM) + 10% FBS
Roswell Park Memorial Institute (RPMI) + 10% FBS
Ham’s F12 + 10% FBS
1:1 DMEM/F12 +10% FBS
Figure 6. Flow cytometry of dissociated irradiated tumor show presence of CD11b+ cells contain a mixture of CD45-low cells (microglia) and CD45-
high cells (macrophage/monocytes) and Ly6G+ neutrophils.
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Further information and requests for resources and reagents should be directed to and will be ful-
filled by the lead contact, Malay Haldar (mhaldar@pennmedicine.upenn.edu).
Materials availability
This study did not generate new unique reagents.
Data and code availability
The accession number for the scRNA-seq data reported in this paper is GEO: GSE166691.
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